Soleno Therapeutics Overview
Latest P/E ratio for Soleno Therapeutics: 27.09 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow27.09
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Soleno Therapeutics (SLNO) currently reports a P/E ratio of 27.09. That is above the Healthcare sector average of 25.9. Use the charts on this page to explore Soleno Therapeutics's P/E ratio history and peer comparisons.
Soleno Therapeutics's P/E ratio of 27.09 is higher than the Healthcare sector average of 25.9. That is roughly 4.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Soleno Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At 27.09, SLNO can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of 27.09, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.9. From there, open related valuation or income-statement pages for Soleno Therapeutics, and consider following SLNO for alerts when major investors trade the stock.
Soleno Therapeutics is classified in the Healthcare sector. On P/E ratio, it currently shows 27.09 versus a sector average near 25.9. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SLNO with unrelated industries.
